- Stocks
- Pharma & Healthcare
- Gland Pharma
Gland Pharma share price
NSE: GLANDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Gland Pharma at a glance
Gland Pharma (NSE: GLAND) closed at ₹2,910.60 on 22 Oct 2026, down 0.66% on the day. With a market capitalisation of ₹48,013 Cr, it ranks 198th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 9.9% in FY26. Over the past year the share price has risen 52.0%. Its 52-week range is ₹1,573.60 (16 Mar 2026) to ₹3,171.00 (7 Oct 2026); the last close is 8.2% below the high. Promoters held 51.77% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹48,013 CrRank 198 on NSE
- P/E (trailing)
- 46.7×
- Price to book
- 2.7×FY26
- ROE
- 9.9%FY26
- ROCE
- 14.0%FY26
- Debt to equity
- 0.02FY26
- Net profit margin
- 16.0%FY26
- Book value / share
- ₹628.67FY26
- 52-week high
- ₹3,171.007 Oct 2026
- 52-week low
- ₹1,573.6016 Mar 2026
- 1-year return
- +52.0%
- RSI (14-day)
- 44.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.66% | −4.5% | −0.8% | +20.3% | +52.0% |
Gland Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,463 Cr | ₹4,401 Cr | ₹3,625 Cr | ₹5,665 Cr | ₹5,617 Cr | — |
| Operating profit | ₹1,335 Cr | ₹1,619 Cr | ₹1,111 Cr | ₹1,133 Cr | ₹1,063 Cr | — |
| Net profit | ₹997 Cr | ₹1,212 Cr | ₹781 Cr | ₹772 Cr | ₹699 Cr | — |
| EPS (₹) | ₹63.00 | ₹74.00 | ₹47.00 | ₹47.00 | ₹42.00 | — |
| Cash from operations | ₹605 Cr | ₹791 Cr | ₹364 Cr | ₹997 Cr | ₹915 Cr | — |
| Total debt | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹107 Cr | ₹78 Cr | ₹70 Cr |
| Shareholders' equity | ₹5,903 Cr | ₹7,158 Cr | ₹7,959 Cr | ₹8,724 Cr | ₹9,151 Cr | ₹10,358 Cr |
Gland Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% |
| Foreign institutions | 6.90% | 7.39% | 7.91% | 7.58% | 7.30% | 8.74% |
| Domestic institutions | 33.27% | 32.85% | 32.64% | 32.98% | 33.35% | 30.44% |
| Non-institutions | 7.99% | 7.93% | 7.63% | 7.61% | 7.52% | 9.05% |
Gland Pharma vs peers
The listed Pharma & Healthcare companies nearest to Gland Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASTERDMAster DM Health | ₹647.20 | −0.46% | −5.5% | ₹56,415 Cr | 101.1 | — |
| FORTISFortis Healthcare | ₹720.15 | −0.67% | −33.5% | ₹54,368 Cr | 52.3 | — |
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹54,244 Cr | 117.6 | — |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹54,069 Cr | 34.8 | — |
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹49,038 Cr | 43 | — |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹48,013 Cr | 46.7 | — |
| ANTHEMAnthem Biosciences | ₹802.40 | −0.52% | +3.0% | ₹45,206 Cr | 76.6 | — |
Ask anything about Gland Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against GLAND's own history. Try: “Why has GLAND moved over the last three months?” · “Backtest a 50-day moving-average crossover on GLAND over five years” · “Compare GLAND with ASTERDM on margins and valuation”
Frequently asked questions about Gland Pharma
What is the share price of Gland Pharma today?
Gland Pharma (NSE: GLAND) last closed at ₹2,910.60 on 22 Oct 2026. Its 52-week high is ₹3,171.00 and its 52-week low is ₹1,573.60.
What is the market cap of Gland Pharma?
Gland Pharma's market capitalisation is ₹48,013 Cr (₹48,013 Cr) at the 22 Oct 2026 close, ranking 198th among the NSE companies Pivot tracks.
What is the P/E ratio of Gland Pharma?
Gland Pharma trades at a trailing P/E of 46.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 76.6.
What is the ROE and ROCE of Gland Pharma?
Return on equity was 9.9% in FY26 and return on capital employed was 14.0% in FY26 (consolidated figures).
Is Gland Pharma a debt-free company?
Gland Pharma is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.
How has Gland Pharma stock performed over the last year?
Gland Pharma's share price has risen 52.0% over the past year, +20.3% over three months and −0.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Gland Pharma?
As of 30 Jun 2026: promoters 51.77%, foreign institutions 8.74%, domestic institutions 30.44%, non-institutions 9.05%.
Who are Gland Pharma's competitors?
The listed Pharma & Healthcare companies closest to Gland Pharma by market cap are Aster DM Health, Fortis Healthcare, Biocon, Abbott India, IPCA Laboratories and Anthem Biosciences.
Is Gland Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gland Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLAND against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text